• info@proteinlounge.com

Animations

Animations

Anti-PD-1 PD-L1 therapy of human cancer

Description

PD-L1,a 40kDa type 1 transmembrane protein, is a PD-1 ligand that can deliver inhibitory signals to PD-1+ T-cells to suppress immune responses. PD-L1 is widely expressed in cancer, where it contributes to immune evasion and facilitates tumor growth.

Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. More specifically, therapies that inhibit the interaction between PD-L1, present on the surface of tumor or antigen-presenting cells, and PD-1, present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic.

Browse Other Animations

Mitosis
Mitosis is the process of cell division which separates the chromosomes in its cell nucleus into[...]
Omicron : The new SARS-CoV-2 Variant
The Omicron or B1.1.529 is a new variant of SARS-CoV-2, first reported to the World Health[...]
siRNA Pathway
Small interfering RNAs (siRNAs) are 2123nt dsRNA (double-stranded RNA) molecules that facilitate[...]
Introduction to Breast Cancer
Breast cancer is a kind of cancer that develops from breast cells. Breast cancer usually starts off[...]
logo

 

9853 Pacific Heights Blvd.
Suite D., San Diego, CA 92121, USA

Tel: 858-224-2869
Fax: 858-205-1192
info@proteinlounge.com

Institutional License

Need our databases and tools to be availed by your whole university or institute? We recommend signing up for our Site License.

To set up a license, please contact: info@proteinlounge.com

Copyright © Protein Lounge Inc.
   Terms & Conditions